Antitrust Settlement

GlaxoSmithKline PLC
08 July 2004

         GlaxoSmithKline Agrees To Settle Augmentin Anti-trust Litigation


GlaxoSmithKline (GSK) today announced that that it has agreed to settle US
anti-trust cases involving the antibiotic product Augmentin.  GSK will pay $92
million (£50 million) in settlement of class action lawsuits brought on behalf
of direct purchasers, including pharmaceutical wholesalers, and indirect
purchasers such as consumers and third party payers.*  The settlements are being
submitted for review to the U.S. District Court for the Eastern District of
Virginia, where the cases have been pending since 2002.  GSK continues to
believe that its actions were appropriate in obtaining and enforcing its patents
for Augmentin.

GSK is also progressing towards settlement of certain other legal matters for
which additional provision is required.

The settlement of all these legal matters will be covered using existing
provisions together with an additional legal charge which will be taken in the
Company's earnings in the second quarter of 2004. This legal charge is expected
to be approximately £170 million and will be largely offset by gains realised
from the sale of equity investments and other income. Taken together, these
items are therefore expected to have minimal impact on the second quarter's
earnings.

GSK's 2004 earnings guidance remains unchanged with the Company expecting to
deliver EPS (at constant exchange rates) at least in line with business
performance EPS in 2003.


S M Bicknell
Company Secretary
8 July 2004



GlaxoSmithKline one of the world's leading research-based pharmaceutical and
healthcare companies is committed to improving the quality of human life by
enabling people to do more, feel better, and live longer.  For company
information and a copy of the company's product development pipeline, visit GSK
at www.gsk.com.



* Further details of the case are available in the company's 2003 Annual Report
(page 119).



Enquiries:

UK Media enquiries:                         Martin Sutton           [phone]
                                            David Mawdsley          [phone]
                                            Chris Hunter-Ward       [phone]

US Media enquiries:                         Nancy Pekarek           [phone]
                                            Mary Anne Rhyne         [phone]
                                            Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:        Duncan Learmouth        [phone]
                                            Anita Kidgell           [phone]
                                            Philip Thomson          [phone]

US Analyst/ Investor enquiries:             Frank Murdolo           [phone]
                                            Tom Curry               [phone]



                      This information is provided by RNS
            The company news service from the London Stock Exchange                   FE